Meropenem Hikma

Meropenem, the active ingredient in Meropenem Hikma, is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous use. It treats a broad range of serious bacterial infections in adult and pediatric patients when other therapies are unsuitable, including intra‑abdominal, urinary tract, respiratory, skin and soft‑tissue, and central nervous system infections and sepsis.

GNH USA supplies Meropenem Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide, ensuring reliable quality and regulatory conformity.

Meropenem is a broad‑spectrum carbapenem antibiotic used to treat severe infections caused by susceptible bacteria.

- Intra‑abdominal infections: effective against mixed aerobic and anaerobic organisms, helping resolve peritonitis and postoperative infections. - Complicated urinary tract infections: eradicates resistant Gram‑negative pathogens, improving outcomes in pyelonephritis and cystitis. - Hospital‑acquired pneumonia: provides coverage for multidrug‑resistant organisms in lower respiratory tract infections. - Skin and soft‑tissue infections: combats severe cellulitis and wound infections caused by resistant bacteria. - Bacterial meningitis: penetrates the cerebrospinal fluid to treat central nervous system infections.

Meropenem may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Headache - Rash - Elevated liver enzymes

Serious or Rare Side Effects: - Seizures, especially in patients with renal impairment or CNS disorders - Anaphylactic or severe hypersensitivity reactions - Clostridioides difficile‑associated colitis - Severe neutropenia or thrombocytopenia - Acute renal failure - Stevens‑Johnson syndrome or toxic epidermal necrolysis

When using Meropenem, clinicians should consider several precautionary measures to minimize risk.

- Renal function: adjust dose in patients with impaired renal clearance. - Allergy: avoid in individuals with known hypersensitivity to carbapenems or other β‑lactams. - Seizure risk: monitor closely in patients with a history of seizures or central nervous system disorders. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Drug interactions: review concomitant medications for possible interactions. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Meropenem can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: meropenem reduces serum levels, increasing risk of breakthrough seizures. - Probenecid: may increase meropenem concentrations, raising the potential for toxicity.

Moderate Interactions (Monitor Closely): - Aminoglycosides (e.g., gentamicin): additive nephrotoxic effect; monitor renal function. - Loop diuretics (e.g., furosemide): may enhance ototoxicity when combined with aminoglycosides. - Warfarin: meropenem may alter INR; frequent coagulation monitoring is advised.